PHPN Stock Overview
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Galectin Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.02 |
| 52 Week High | US$3.88 |
| 52 Week Low | US$1.16 |
| Beta | 0.88 |
| 1 Month Change | 42.45% |
| 3 Month Change | 96.10% |
| 1 Year Change | 96.10% |
| 3 Year Change | -12.72% |
| 5 Year Change | -21.60% |
| Change since IPO | -37.08% |
Recent News & Updates
Recent updates
Shareholder Returns
| PHPN | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.8% | -0.2% | 0.5% |
| 1Y | 96.1% | -22.8% | 1.3% |
Price Volatility
| PHPN volatility | |
|---|---|
| PHPN Average Weekly Movement | 12.5% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: PHPN's share price has been volatile over the past 3 months.
Volatility Over Time: PHPN's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 28 | Joel Lewis | galectintherapeutics.com |
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with nonalcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration.
Galectin Therapeutics Inc. Fundamentals Summary
| PHPN fundamental statistics | |
|---|---|
| Market cap | €189.85m |
| Earnings (TTM) | -€41.77m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.8x
P/E RatioIs PHPN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHPN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$44.81m |
| Earnings | -US$44.80m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.72 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -119.1% |
How did PHPN perform over the long term?
See historical performance and comparison